[go: up one dir, main page]

WO2025099450A1 - Pâte dentaire - Google Patents

Pâte dentaire Download PDF

Info

Publication number
WO2025099450A1
WO2025099450A1 PCT/GB2024/052849 GB2024052849W WO2025099450A1 WO 2025099450 A1 WO2025099450 A1 WO 2025099450A1 GB 2024052849 W GB2024052849 W GB 2024052849W WO 2025099450 A1 WO2025099450 A1 WO 2025099450A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
paste
microbiome
composition
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/GB2024/052849
Other languages
English (en)
Inventor
Glen Francis VILE
Ann Kimberly HAIGH
Alice DENYER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lintbells Ltd
Original Assignee
Lintbells Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lintbells Ltd filed Critical Lintbells Ltd
Publication of WO2025099450A1 publication Critical patent/WO2025099450A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • a bioactive component intended to maintain and/or improve health in a human or an animal, such as a companion animal presents varying challenges to formulators, particularly depending on the target site and type of agent for delivery.
  • Many bioactive agents are susceptible to degradation and exposure to oxygen, heat, light and/or moisture may practically negate the health benefit of the bioactive.
  • the formulation used to deliver the bioactive component may comprise a solid dose form, such as a capsule or tablet because inherent protection of the active is required.
  • traditional encapsulation or other processing methods that provide a physical barrier to help reach/access the target site successfully are not always useful.
  • the mouth which defines the oral cavity of mammals, humans or animals such as pets, comprising the oral mucosa (gums, lips, cheeks, palate and floor of the mouth), the tongue and the teeth.
  • the formulation is required to remain proximal and remain local for a minimum period such that the bioactive component is delivered at the required efficacy.
  • many oral health products formulated for use in the mouth such as oral washes, lozenges, and pastes, suffer the problem of unreliable and/or inconsistent delivery and a sufficient amount of the bioactive (on the mucosal membrane or tongue, for example) is never achieved which to yield a measurable effect.
  • tooth decay and/or gum disease may start to occur in the mouth of the mammal, especially if teeth e.g. of pet animals, are not regularly cleaned to remove buildup of plaque.
  • Colonization of the pathogenic species is known to weaken and then dissolve dental enamel leading to caries, or lesions in the teeth and calcified deposits begin to form providing localized focus for the colony to continue to thrive on the teeth, thereby aggravating the problem.
  • These processes contribute to the frequently recorded symptoms of poor oral health: such as malodor of breath, inflammation and bleeding of the gingival tissue and gum.
  • oral care products including those used in veterinary field, often include a bactericidal agent to reduce the pathogen levels.
  • EP3424516 suggests a composition comprising binder lactic acid bacterium microorganism that is sensorically [sic] neutral and reduces Streptococci colonies. The composition may be added to pet food and does not suffer the taste/smell that the authors suggest typically prevent such compliance by a companion animal with use of effective bactericides.
  • the invention disclosed herein concerns a dental paste or gel comprising a composition having at least 2 to 4 % w/w of a thickening agent, preferably agar; 62 to 95 % w/w glycerol; and 0.03 to 3 % w/w of an epithelial-adhering protein complex (EAPC).
  • the epithelial-adhering protein complex may comprise one or more: 1) microbiome regulating proteins or a “protein fraction” and 2) a modified whey protein isolate (WPI) from milk.
  • the microbiome regulating protein (s) may be selected from lactoperoxidase, lactoferrin, lysomal alpha-mannosidase, immunoglobulin G, angiogenin, ribonuclease 4 or quiescin sulfhydryl oxidase and/or combinations thereof.
  • the modified WPI is formed from soluble native protein, protein aggregates and protein fibrils produced from whey protein isolates (WPIs).
  • WPIs whey protein isolates
  • the dental paste or gel may be applied effectively by brushing or coating structures in the oral mucosa directly. The novel form of the dental paste ensures the complex is maintained at the application location i.e. near the relevant structure, such as the gum and teeth.
  • the glycerol component comprises at least 90 to 95% w/w.
  • the composition comprises at least 0.03% w/w epithelial-adhering protein complex, optionally this component is present in the range of at least 0.1 to 3%, 0.5 to 3%, 1 to 3%, 2 to 3% or 2.5 to 3% w/w.
  • the composition of the invention may comprise up to 32% w/w of other/further excipients designed to improve the texture of the composition including further thickening, or stabilising agents, such as chitosan or rice flour.
  • the paste or gel is for use in the treatment or prevention of oral disease, specifically canine oral disease mediated by an excess of pathogenic bacteria.
  • the oral disease may be selected from but not limited to any of tooth decay, gum inflammation and/or calculus.
  • the paste or gel composition may also be for use in veterinary treatment to restore animal oral health, particularly canine or feline oral health.
  • the dental paste is useful to combat stubborn, adverse oral health conditions, such as a bacterial infection in an animal, particularly where disease may be due to an increase in pathogenic bacteria. As described previously, an increase in the pathogenic bacteria typically causes adverse oral health including one or more of bad breath (halitosis), plaque and/or gum disease in animals.
  • Lactoperoxidase activity was therefore measured by the addition of the dental paste as provided in Example 3 of the table above, to a solution of hydrogen peroxide in 100 mM Phosphate buffer, pH 5.5, and monitoring the oxidation of 2,2-Azino-bis(3-Ethylbenzthiazoline-6-sulphonicacid) (ABTS) spectrophotometrically at 436nm.
  • ABTS 2,2-Azino-bis(3-Ethylbenzthiazoline-6-sulphonicacid)
  • Lactoperoxidase activity of the combination of the microbiome regulating proteins formulated from the complex within the dental paste was retained and these levels are approximately what would be expected in the original complexed form indicating that formulating the EAPC further into the new dental paste does not reduce the biological activity of the antibacterial component.
  • Bioactivity - Confirmatory studies Further testing to confirm bioactivity following formulation of the bioactive component i.e. the microbiome regulating protein within the epithelial-adhering protein complex when combined with the recited components and provided within the final formulation of the dental paste of the invention was undertaken.
  • EAPC epidermal-adhering protein complex
  • the components were in accordance with the various embodiments of the invention described above.
  • the water component was included only for consistency in formulation, and in particular to avoid heating the glycerol, to ensure no potential denaturing of the bioactive in the process of formulation and testing.
  • In vitro confirmation of comparative activity in pastes Initial indication that activity could be maintained in the formulated dental paste was then required to be confirmed by additional in vitro testing. Two linked indicators were tested to confirm that activity. Lactoperoxidase is one of the enzyme proteins that is selectively fractionated into the microbiome regulating component of the epithelial- adhering protein complex in the formulation. Re-confirming activity of lactoperoxidase in the final formulated paste would therefore be indicative that necessary activity was present for the intended applications.
  • the enzyme activity of the paste with the batch of microbiome regulating protein that was active gave a paste that was active, as expected.
  • the trial dental paste was much greater than the low activity paste, but compared to the active paste with only the microbiome regulating protein of the same batch some activity was lost.
  • the decrease in lactoperoxidase activity may have occurred during the manufacture of the EAPC.
  • the dose of each paste delivered the same amount (0.08 mg/ml) of the microbiome regulating protein component into the bacteria culture solution sample. Growth rate of B.
  • subtilis with no paste was determined to be akin to the growth rate in the presence of the low activity paste, growing to a maximum OD of around 0.25, after 760 mins as seen in Figure 5.
  • the active microbiome regulating protein only paste inhibited the growth rate of B. subtilis more than the low activity paste.
  • the dental paste of the invention completely inhibited B. subtilis growth over the period investigated. This suggests when presented with a biological challenge the activity of a comparable concentration of the bioactive component when provided in a form in accordance with the invention may be enhanced.
  • the three pastes were increasingly diluted into the bacteria culture solutions and the bacterial growth was measured after 500 minutes, while the bacteria were still in a state of rapid growth.
  • the results are visually illustrated in the graph of Figure 6, and the minimum inhibitory concentration (MIC) of the pastes is as follows: Sample Name Microbiome Minimum inhibitory regula ⁇ ng concentra ⁇ on protein (Microbiome regula ⁇ ng batch protein content mg/ml) Trial Dental paste 18713 0.02 Ac ⁇ ve (microbiome regula ⁇ ng protein only) paste 18713 0.93 Low ac ⁇ vity paste 19317 >0.93
  • the microbiome regulating protein was effective at reducing the growth rate of B.
  • subtilis quickly from 0.15 mg/ml but did not fully inhibit growth until concentration was at 0.93 mg/ml.
  • the low activity paste was required to be in a much higher concentration to inhibit growth and did not inhibit relative growth to a level to lower than 70% (i.e. did not fully inhibit).
  • the trial dental paste was significantly more effective at preventing the growth of B. subtilis than either of the two other pastes, despite having been prepared from the same amount and from the same batch (18713) as the active microbiome regulating protein only paste.
  • the trial dental paste appears to demonstrate a significant level of antimicrobial activity, much higher than expected from its microbiome regulating protein content.
  • Dogs were required to have a significant dental condition at the start of the trial in accordance with the following grading authority: Wisconsin Department of Agriculture, Trade and Consumer Protection and Division of Animal - Grading Canine Dental Condition: https://datcp.wi.gov/Documents2/CanineDentalGradeChart.pdf.
  • grading authority Wisconsin Department of Agriculture, Trade and Consumer Protection and Division of Animal - Grading Canine Dental Condition: https://datcp.wi.gov/Documents2/CanineDentalGradeChart.pdf.
  • MINOR / GRADE 1 Soft plaque has built up on the surface of the teeth. A small amount of tartar is also present. Tartar was formed when mineral deposits from saliva precipitated in plaque. Bacteria have grown, multiplied and invaded the gum tissues around the tooth causing early gingivitis, and red, inflamed gums.
  • Roots are infected, abscessed, and rotten. The thin wall of bone surrounding teeth has deteriorated, and many teeth are loose. Bacteria may be spreading through the entire body in the bloodstream, potentially causing harm to vital organs. Pain can also be severe at this stage.
  • Trial Protocol Participants received one tube of dental paste (trial dental paste or placebo paste) and two kits for taking oral swabs. All were instructed to follow the trial protocol: Day 1 Collect baseline oral swab: wipe the swab tip in a rolling motion along the ⁇ upper right gum line for 15 seconds. Insert the swab into the collection tube and follow the instructions supplied with the swabbing kit to prepare the sample for transport.
  • the abundance of bacteria in the oral cavity of the dogs was determined from long-read 16S mRNA sequencing of the material on swabs taken from the oral cavity of dogs in the treatment group (given trial paste made in accordance with an example of the invention, containing the before described EAPC (epithelial-adhering protein complex) and dogs in the placebo paste group (the paste not containing the EAPC).
  • the species of bacteria were determined from the 16S mRNA sequences. Key pathogenic species typically associated with canine oral health were identified from the literature. For example, the species described in “Assessment of changes in the oral microbiome that occurs in dogs with periodontal disease (2021) Santibanez R et al.
  • the trial dental paste or gel according to the above-described embodiments is likely useful as a veterinary medicament. Moreover, this maybe in the treatment protocol wherein the paste is effective by daily application. Such a dental paste is therefore likely to help prevent oral disease mediated by an excess of pathogenic bacteria in mammals and/or animals, particularly canines.
  • the dental paste of the invention may be particularly useful when oral disease includes one or more of the following symptoms: tooth decay, gum inflammation, calculus, periodontal disease, halitosis.
  • a chew or animal toy at least partially coated with or comprising the dental paste or gel as before described may be beneficial in the maintenance of oral health in an animal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un gel ou une pâte ayant une composition comprenant au moins 2 à 4 % p/p d'agent épaississant, éventuellement de l'agar, au moins 50 à 95 % p/p de glycérol et au moins 0,03 à 3 % p/p de complexe protéique adhérant à l'épithélium. Le gel ou la pâte de l'invention est formulé pour assurer et maintenir un effet local et tangible à partir de l'activité du complexe protéique dans la muqueuse buccale afin de permettre la restauration et l'entretien de la santé buccale chez un mammifère, ou un animal, tel qu'un chien.
PCT/GB2024/052849 2023-11-10 2024-11-08 Pâte dentaire Pending WO2025099450A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2317287.7A GB2636062A (en) 2023-11-10 2023-11-10 Dental paste
GB2317287.7 2023-11-10

Publications (1)

Publication Number Publication Date
WO2025099450A1 true WO2025099450A1 (fr) 2025-05-15

Family

ID=89225142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2024/052849 Pending WO2025099450A1 (fr) 2023-11-10 2024-11-08 Pâte dentaire

Country Status (2)

Country Link
GB (1) GB2636062A (fr)
WO (1) WO2025099450A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003727A1 (fr) * 1999-07-07 2001-01-18 Perraudin Jean Paul Nouveaux procedes et medicament pour le traitement de maladies infectieuses faisant intervenir des biofilms microbiens
NZ547859A (en) 2006-06-09 2009-05-31 Dec Int Nz Ltd Treatment method and composition for mastitis
WO2009068602A2 (fr) * 2007-11-30 2009-06-04 Glaxo Group Limited Nouvelle utilisation
EP1449513B1 (fr) * 2003-02-19 2013-04-10 Unilever PLC Produit de soins dentaires
EP3424516A1 (fr) 2011-01-24 2019-01-09 Basf Se Compositions améliorant la santé buccale
WO2019222124A1 (fr) * 2018-05-14 2019-11-21 The Procter & Gamble Company Compositions moussantes pour l'hygiène buccale
CN111437383A (zh) * 2020-06-05 2020-07-24 广州赛葆力医疗器械有限公司 一种口腔护理用组合物及其应用
WO2022051227A1 (fr) * 2020-09-02 2022-03-10 Colgate-Palmolive Company Compositions d'hygiène buccale
WO2023153945A1 (fr) * 2022-02-14 2023-08-17 Quantec Limited Combinaison, utilisations thérapeutiques et utilisations prophylactiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4082782B2 (ja) * 1998-04-30 2008-04-30 雪印乳業株式会社 歯周病予防及び改善剤
US12005100B2 (en) * 2016-04-21 2024-06-11 Quantec Limited Combination, therapeutic uses and prophylactic uses
CN110840788B (zh) * 2019-11-27 2022-04-19 广东盐业健康产业发展有限公司 一种牙膏配方
GB2618609A (en) * 2022-05-13 2023-11-15 Lintbells Ltd Methods and processes for manufacture of a topically adherent selective bactericide

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003727A1 (fr) * 1999-07-07 2001-01-18 Perraudin Jean Paul Nouveaux procedes et medicament pour le traitement de maladies infectieuses faisant intervenir des biofilms microbiens
EP1449513B1 (fr) * 2003-02-19 2013-04-10 Unilever PLC Produit de soins dentaires
NZ547859A (en) 2006-06-09 2009-05-31 Dec Int Nz Ltd Treatment method and composition for mastitis
WO2009068602A2 (fr) * 2007-11-30 2009-06-04 Glaxo Group Limited Nouvelle utilisation
EP3424516A1 (fr) 2011-01-24 2019-01-09 Basf Se Compositions améliorant la santé buccale
WO2019222124A1 (fr) * 2018-05-14 2019-11-21 The Procter & Gamble Company Compositions moussantes pour l'hygiène buccale
CN111437383A (zh) * 2020-06-05 2020-07-24 广州赛葆力医疗器械有限公司 一种口腔护理用组合物及其应用
WO2022051227A1 (fr) * 2020-09-02 2022-03-10 Colgate-Palmolive Company Compositions d'hygiène buccale
WO2023153945A1 (fr) * 2022-02-14 2023-08-17 Quantec Limited Combinaison, utilisations thérapeutiques et utilisations prophylactiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NIEMIEC B ET AL.: "The bacteriome of the oral cavity in healthy dogs and dogs with periodontal disease", AMERICAN JOURNAL OF VETERINARY SCIENCE, vol. 83, 2021, pages 1
RIGGIO MP ET AL.: "Molecular identification of bacteria associated with canine periodontal disease", VETERINARY MICROBIOLOGY, vol. 150, 2011, pages 3 - 4
SANTIBANEZ R ET AL.: "Assessment of changes in the oral microbiome that occurs in dogs with periodontal disease", VETERINARY SCIENCES, vol. 8, 2021, pages 291

Also Published As

Publication number Publication date
GB202317287D0 (en) 2023-12-27
GB2636062A (en) 2025-06-11

Similar Documents

Publication Publication Date Title
CN101687002B (zh) 葫芦巴的提取物
JP3334879B2 (ja) 抗胃障害製剤組成物
US7946849B2 (en) Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy
EP3324928B1 (fr) Composition pour soins buccaux auto-filmogène
US20040126440A1 (en) Periodontal treatment compound and method of use
US8722080B2 (en) Treatment and prevention of dental pathology in humans and non-human animals
EP1988903A2 (fr) Methode de conservation de l'hygiene orale chez les animaux utilisant des derives de morpholine
JPH0686380B2 (ja) 殺菌剤とその製造方法
US20250375481A1 (en) Methods and processes for manufacture of a topically adherent selective bactericide
WO2025099450A1 (fr) Pâte dentaire
CN1173323A (zh) 用于增进口腔卫生的组合物
CN107441019B (zh) 一种宠物用牙膏及其制备方法
CN109512683A (zh) 一种聚维酮碘组合物及其制备方法与应用
EP3782633B1 (fr) Composition de cavité buccale pour animal, et agent de prévention de maladie parodontale, agent de prévention de maladie infectieuse, et agent de prévention de l'halitose pour animal
US20090317364A1 (en) Novel compositions for prevention and treatment of mastitis and metritis
US20060034783A1 (en) Novel method for treating periodontal disease
Soekanto et al. Tooth Coating Gel with Casein Phosphopeptide–Amorphous Calcium Phosphate and Propolis to Prevent Dental Caries
CN101288769A (zh) 一种用于宠物的杀菌制剂及其制备方法
CA2370784C (fr) Fibres endodontiques et leurs methodes d'utilisation
US20240156883A1 (en) Oral composition for animal and periodontal disease preventive, infection disease preventive, and mouth odor preventive using the oral composition
RU2820286C1 (ru) Средство в форме геля для ухода за полостью рта животных
Hennet Canine nutrition and oral health
JP5090578B2 (ja) 動物用口腔内滞留剤、動物用口腔内環境改善剤および動物用口腔内環境改善方法
TW202432155A (zh) 抑制植體周圍炎的組成物及其用途
Lindinger Research Article Reduced Dental Plaque Formation in Dogs Drinking a Solution Containing Natural Antimicrobial Herbal Enzymes and Organic Matcha Green Tea

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24808711

Country of ref document: EP

Kind code of ref document: A1